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ABSTRACT
India is one of the top producers of generics globally and is currently being recognized as the “pharmacy of the world” for the generic drug products. 
Thus, there is a need that it has best health-care systems in place to regulate and provide better quality drugs by monitoring the possible risk 
associated with the use of drugs. Being the generic hub, physicians, pharmacists, etc., should be erudite to provide an alternative cost-effective generic 
medicine, which is one of the education-related aspects of pharmacovigilance. We need a more systematic approach to surveillance of drug-related 
problems, which is at the heart of pharmacovigilance. The health-care system requires new processes to understand the risk-benefit ratio of drugs. 
The challenges in implementation of better pharmacovigilance in country due to nonavailability of trained staff in pharmacovigilance, lack of training 
of health-care professionals on drug safety, and adverse drug reaction reporting which comprises adverse interactions of medicines with chemicals, 
other medicines, and food are often neglected leading to under-reporting by health-care professionals as well as patients, lack of expertise, etc., should 
be overcome by Indian regulatory body via practical oriented knowledge-based system. The web market monitoring, global electronic database, 
education, association of stakeholders and regulation of herbal medicines standards and allied medicinal systems are vital restructurings needed to 
be introduced for a better pharmacovigilance system in India.
INTRODUCTION
As per the World Health Organization (WHO), pharmacovigilance 
is the “Science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects (AEs) or any other 
drug-related problem” [1]. Every drug has its beneficial pharmacological 
activity as well unavoidable side effects. The risk can be minimized 
by better quality drugs, awareness among patients and the right 
therapeutic decision by health-care professionals. Pharmacovigilance 
helps in reducing these risks by understanding the safety profile of 
drugs and forecasts the serious adverse drug reaction (ADR) based 
on the information. Pharmacovigilance has not developed in India to 
that extent than it has in western countries. Reasons: Inadequacy of the 
health-care system, lack of awareness among people regarding proper 
usage of medicines and no urgency by the government to establish the 
proper pharmacovigilance system. In the USA, the laws regarding drug 
safety monitoring were applied in 1962, in Europe around 1963-1964. 
However, in India 1997, this when India joined WHO-ADR monitoring 
program with 3 centers nationwide [2]. However, an appreciable 
program has been initiated by Central Drugs Standard Control 
Organization (CDSCO) under Government of India, a nationwide 
pharmacovigilance program in July 2010, for monitoring ADR in the 
country to safe-guard public health [3].
In recent years, India has become hub for clinical research activities due 
to its large population, high enrolment rate, and low cost. However, its 
first time availability in the USA or European market and later in India, 
results in unavailability of long-term safety data of such drugs. In such 
scenarios, Indian regulatory bodies cannot rely on safety data of other 
markets to assess the risk-benefit balance of a drug, thereby implying 
the importance of our very own pharmacovigilance systems.
 PHARMACEUTICAL COMPANIES
Pharmaceutical companies are one of the keys connect in the chain 
of pharmacovigilance system. The Indian regulatory agency should 
make pharmacovigilance reporting mandatory for all pharmaceutical 
companies who are marketing their drugs in India. Pharma companies 
should maintain database all ADRs reported to them via consumers or 
health-care professionals. A pharmaceutical company can accomplish 
this either by setting up in-house systems for pharmacovigilance or by 
contractual agreements with clinical research organizations (CROs) [4]. 
The company should be accountable to submit ADRs postmarketing of 
drugs and even during the clinical trials. The regulatory agency should 
introduce pharmacovigilance inspections. The companies should have 
ethical consideration for event reporting during clinical trials as well 
as postmarketing of the drugs. To reduce the administrative burden, 
they can outsource work to different CROs. These practices are already 
followed by global companies who have affiliates across the world 
nevertheless; Schedule Y of the Drugs and Cosmetics Act 1945 does 
not insist on anything concerning the expedited reporting of serious 
adverse reactions from other nations. This is one of the major loopholes 
in pharmacovigilance structure of India [5].
DRUG USAGE
Most of the ADRs reported worldwide are related to improper drug 
administration and incorrect usage. Examples of such ADRs are 
medication errors, lack of efficacy reports, intentional drug misuse, 
drug abuse, improper administration of the drug especially injectables, 
injection site reactions [6]. Public awareness should be created 
regarding the drug use. Reducing ADR occurrences can be a highlight 
for effective pharmacovigilance. The drug usage should also be taken 
into account and safety profile of the drug on its utilization pattern can 
be monitored. The drug utilization studies should be carried out based 
on the pattern of use, quality of use, and outcome of use. This will give 
an idea for ADR occurrences and can be relevant for drug development 
and prescription practices. It also provides insight into the efficiency 
of drug use, i.e., whether a certain drug therapy provides value for 
money. The benefit, harm, effectiveness, and risk of medicines should 
be communicated to the public and patients to circumvent ADRs as well 
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as to make them aware consumption of drugs. For instance, during a 
pandemic of H1N1 influenza, European Medicines Agency issued a 
press release on reiterating the efficacy and safety of the centrally 
authorized vaccines, it turned out to be affirmative, and no unforeseen 
serious safety issues had been identified [7]. There is need of rational 
drug usage. ADRs cases can be associated with the patterns of drug 
use within the public, which arises due to unreasonable drug use, drug 
interactions, medication errors, self-medication, etc.
GLOBAL ELECTRONIC DATABASE
With the help of IT sector, vigorous electronic database for 
pharmacovigilance system of India should be built. It should provide 
risk-benefit ratio of the drug via computer algorithms that statistically 
measures the reporting frequency for huge numbers of drug-event 
combinations are increasingly and helps screening large spontaneous 
reporting system databases and review of health statistics and drug 
utilization data [8]. The databases containing patient profiles, physician 
profiles, clinical trials ADRs, spontaneous reporting submissions, etc., 
should be established. The database must incorporate Medical Dictionary 
for Regulatory Activities and E2B to follow international guidelines. The 
database will help to identify specific product AE combinations against 
marginal distributions as a background and can be used for research 
purposes too. It should also include drug information and their ADRs 
listings as per the individual pharmaceutical company. A data-driven 
framework for managing the pharmacovigilance of marketed products 
is needed to be launched. The database must, therefore, be validated and 
acceptable to regulatory authorities. The WHO Collaborating Centre, 
the Uppsala Monitoring Centre, can act as guidance for the required 
purpose, which is responsible for the management of the WHO program 
for international drug monitoring [9]. Data quality is crucial to institute 
causality which is the most vital characteristic in the investigation of 
suspect ADR reports. This aids in founding the probable relationship 
of the reaction with the drug. If the reaction is conclusively due to the 
drug supplementary safety measures can be taken while prescribing 
the same medication [10]. Even the statistical method can be used to 
execute organized signal detection of adverse event information.
EDUCATION
INDIAN REGULATORY AGENCY
The most important and chief link in pharmacovigilance system. 
The Pharmacovigilance Programme of India initiated in 2010 is a 
step forward by CDSCO and Ministry of Health and Family Welfare, 
Government of India [14]. It should develop a uniform structure for 
reporting of events nationwide including creating a single nationwide 
specific adverse event reporting form to be used by all, making core 
teams of trained scientific and medical expertise, having global 
knowledge for developing the efficient health-care system.
There is in need to set up our own pharmacovigilance monitoring 
center of global standards. It includes having a national database or 
system for collating and managing ADR reports, the existence of a 
national spontaneous reporting system with a national ADR reporting 
form, training of staff in case assessment, signal analysis and benefit-
risk evaluation, access to the VigiFlow software for management 
of individual case safety reports [15]. Furthermore, it requires 
collaborating with pharmacovigilance organizations in enhancing drug 
safety, working together with CROs, hospitals to train patient as well as 
health-care professional for effective adverse event reporting. National 
Monitoring Centers are important in increasing public awareness of 
drug safety and communication of this information to patients and 
practitioners.
WEB MARKET MONITORING
In this digital age, increasing use of the Internet has resulted in a change 
in access to all pharmaceutical products and information on them, 
giving rise to need of more vigilant safety measures. The introduction 
of e-commerce in the world, which provided convenience to consumers 
along with offers, discounts, and home-delivered products over the 
past decade, also led to the development of the cyber pharma drug 
market [16]. The last decade has seen the rise of new internet tools 
that have acted as important enablers of online drug markets. The 
Internet now hosts a range of virtual marketplaces for selling and 
buying illicit substances, as well as signifying a new arena for health 
and law enforcement involvements [17]. The practices such as illegal 
sale of medicines without prescriptions over the Internet, growing self-
medication practices, manufacture, and sale of counterfeit low-quality 
medicines should be detected to be controlled and curtailed. Therefore, 
in India, the need for regulating online drug sales is as pivotal to 
health care as is the need to have drug sale and distribution regulated, 
otherwise. We need to develop active relationships with the media to 
facilitate effective and accurate communication of drug information to 
the public.
ASSOCIATION OF STAKEHOLDERS
The pharmacists, clinicians, pharmaceutical manufacturers, drug 
developers, regulators, public lawmakers, patients, and the general 
public all have their own harmonizing roles in achieving what is 
envisioned [18]. Patients should also be helped to understand that 
the information they provide is likely to contribute to an international 
understanding of drug safety. There is need to develop a platform that 
encourages debate and discussion between regulators, manufacturers, 
consumers, and the media that would ensure much toward achieving 
effective pharmacovigilance objectives. The strengthening medicine 
safety transparency and communication so that the understanding and 
trust of patients and health professionals in the safety of medicines 
will improve, as well as the penetration of key cautions will lead to the 
better long-term running system [19].
REGULATION OF HERBAL MEDICINES AND ALLIED MEDICINAL 
SYSTEMS
Herbal medicines or ayurvedic medicines are widely used all over the 
country. However, the reports regarding ADR reporting with them is 
low. This does not give an indication anything herbal is safe. It is one 
of the drawbacks that adverse reaction terminology for herbal or 
ayurvedic drugs is not well versed. An even drug-drug interaction is 
overlooked while reporting. The National Pharmacovigilance Centre 
for Ayurveda, Siddha, and Unani (ASU) drugs in India was established 
taking the WHO guidelines for the safety issues of herbal medicines into 
consideration [19]. However, awareness among the public regarding 
the same needs to be focused. A standardization of herbal medicines is 
It means both existing health-care professionals as well as infant stage; 
students  of  the  health-care  system  and  layman  should  be 
educated  about  the  importance  of  pharmacovigilance.  Physicians, 
pharmacists,  and nurses  play a  chief  role  in  pharmacovigilance as 
they are first to detect AEs in patients admitted for treatment [11]. 
They  can  educate  patients  and  their  families  for  the  signs  and 
symptoms that should be reported immediately. Hence, they must have
 accurate and appropriate knowledge about the same for better AE 
reporting.  Thus,  encourage  compliance  with  the  ADR  reporting 
program. The awareness programs, training, and usage of digital media 
to reach to public for the safeguard of their health must be used to 
educate  people  regarding  drugs  and  potential  ADRs.  Adverse 
reactions  tend  to  be  regarded,  falsely,  as  “side  effects”  which  would 
lead to wrong signaling of the drug safety report,  to avoid all  these 
health professionals  and regulators  should be well  educated and 
trained about good safety monitoring. The pharmacy educational
 institutions must integrate pharmacovigilance courses in the 
curriculum  as  one  of  the  subjects  to  give  first-hand  experience  of 
the same [12].  Incessant education of health-care personnel about 
pharmacovigilance  by  oral  demonstrations,  verbal 
aides-mémoires,  delivering  ADR  newsletters/bulletin/case  reports  by 
email, mailing and direct supply for hospital staff, billboard, presence of 
pharmacist  in  the  medical  wards  and  involving  enthusiastically  in 
education  and  training  of  health-care  staffs,  especially  nurses  and 
physicians are needed for development of knowledge, alertness,
 and outlook of health-care personnel about ADRs [45].
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required for getting accepted in the global market as well as identifying 
the adverse reaction caused by them. The herbal medicines behave 
pharmacologically different than allopathic medicines, and thus, 
ADRs manifested are different based on pharmaceutics of a drug. On 
the lines of WHO database for herbs and drug interactions, there is a 
need to develop safety database for ASU system of medicines [20]. The 
monitoring the safety of herbal medicinal products will definitely go a 
long way in restoring the confidence of their safety.
CONCLUSION
The Drug Controller General of India has shown its commitment 
to ensure the safe use of drugs by establishing the National 
Pharmacovigilance Program. The challenges in the implementation 
of better pharmacovigilance in the country due to nonavailability 
of trained staff in pharmacovigilance, lack of training of health-care 
professionals in drug safety and ADR reporting, lack of expertise, etc., 
should overcome by Indian regulatory body via knowledge-based 
systems. For an effective pharmacovigilance system to be functional and 
efficient, all the stakeholders need to be alert and attentive throughout 
the lifecycle of a medicinal product in the market. The health-care 
professionals, patients, and pharmaceutical companies should report 
ADRs by own selves and actively participate in the pharmacovigilance 
system of the country. The system needs to be reviewed timely to 
face future challenges. Ultimately, an effective pharmacovigilance will 
facilitate the competent pool of data from all sources, transformation 
of significant data into information with authorization of the country 
to use this information, enhancing the trends of medicine use in their 
countries, and enable to make judicious therapeutic judgments on the 
usage of medicine. The progression of pharmacovigilance cannot occur 
in inaccessibility; rather, it must be part of a larger effort to improve 
global clinical research and development and reform the regulatory 
system.
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Fig. 1: Factors to be considered for better pharmacovigilance in 
India
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